Articles related to VACCINES

Reports on the Vaccine Safety Datalink flagged the need to investigate a potential increased risk those 65 years of age and older, for ischemic stroke in the first 21 days after receiving the bivalent Pfizer-BioNTech booster. FDA has parallel monitoring systems to confirm or fail to validate a safety signal. In this case, those other systems did not confirm the Vaccine Safety Datalink flag.

Per this Nature article highlighted on MashupMD, inadequate funding plus fears of rebound and side effects are hobbling the availability and use of this potentially lifesaving antiviral.

The original monovalent vaccines continue to protect against serious disease from the new variants. If SARS-CoV-2 variants evolve to resist the protection against severe disease offered by vaccination or previous infection, then variant-specific vaccines will be needed. Otherwise, this authority recommends we “stop trying to prevent all symptomatic infections in healthy, young people by boosting them with vaccines containing mRNA from strains that might disappear a few months later.”

Beliefs and Attitudes Towards Cancer Prevention Among Anti-vaxxers, Flat Earthers, and Reptilian Conspiracists: Online Cross Sectional Survey The fact that more than half of the 1,494 survey respondents agreed that “It seems like everything causes cancer” underscores the challenge society faces in separating real causes from mythological ones as a result of widespread information. Contrary to their counterparts, those who believed in conspiracies, disapproved of the COVID-19 vaccination, or supported alternative medicine were more likely to support the fictitious causes of cancer while being less likely to support the real causes of cancer. These findings imply a clear link between online disinformation and ensuing unhealthy choices, which may account for an additional portion of cancer that is preventable.

We can better understand outcomes in patients with a variety of ages, ethnicities, comorbidities, and exposures by using observational data. It can be challenging or even impossible to disentangle the diverse effects of dynamic elements like vaccination rates, patient behaviors, and COVID-19 pathogenicity. Randomized controlled trials involving blood cancer patients are required to fully assess the impact of COVID-19 therapies. The impact of both bivalent vaccines and prophylactic monoclonal antibodies, as well as ways to assure equitable distribution of COVID-19 vaccines and therapies, will all be determined by future study. Some of those studies must involve people who have hematologic malignancies.

According to a news release from study lead author Colin Haile, a research associate professor of psychology at UH and the Texas Institute for Measurement, Evaluation and Statistics (TIMES) and a founding member of the UH Drug Discovery Institute, “Our vaccine is able to generate anti-fentanyl antibodies that bind to the consumed fentanyl and prevent it from entering the brain, allowing it to be eliminated out of the body via the kidneys.” The person won’t experience the euphoric benefits as a result, and they can “get back on the wagon” to sobriety.